Antag Therapeutics
Therapeutic peptides for the modulation of GIP biologyAntag Therapeutics is a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders.
Our approach is rooted in decades of pioneering research from the University of Copenhagen, with a focus on the complexities of incretin physiology. Antag’s portfolio of GIPR antagonists is inspired by an endogenous GIPR antagonist discovered by the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, extensively studied in numerous human interventional trials.
Focus area
Obesity
According to the WHO, over 890 million adults globally suffer from obesity—a number that continues to rise each year. Obesity is a major driver of serious comorbidities, including type 2 diabetes, fatty liver disease, stroke, coronary artery disease, and cancer, among others. While recent advancements in obesity treatments have delivered promising results, there remains a critical need for complementary therapies to address diverse patient needs and challenges such as accessibility, tolerability, and long-term adherence.
At Antag Therapeutics, we are dedicated to transforming the treatment landscape by developing innovative GIPR antagonist therapies to combat obesity and offer new solutions for patients worldwide.
Our first-in-class therapeutic peptides are optimized analogues of an inhibitor of the GIP receptor that is found naturally in the human body
Team
Chair
Independent
M.Sc. PhD
MD PhD
MSc, MB BChir, MRCP
M.Sc. PhD
M.Sc., MBA
D.V.Sc., PhD
M.Sc. PhD
M.Sc.
M.Sc., Ph.D.
News
Antag Therapeutics Announces €80 Million Series A Financing
DECEMBER 4, 2024
“Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of Denmark (EIFO)…”
Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687
OCTOBER 9, 2024
“We are thrilled to receive the FDA’s acceptance of our IND application for AT-7687,” said Alexander Sparre-Ulrich, CEO of Antag Therapeutics. “This marks a major step forward in advancing our clinical development program and brings us closer to providing a potential new treatment for patients with obesity and cardiometabolic diseases. We are excited to begin our Phase I study and further demonstrate the therapeutic potential of AT-7687 and GIPR antagonism.”
Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors
JULY 15, 2021
Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors.
Novo Seeds invests millions in diabetes venture with huge potential
JUNE 26, 2017
Denmark’s largest business newspaper (Børsen) covers Antag Therapeutic’s launch in this article
Novo Seeds invests millions in new venture
JUNE 26, 2017
MedWatch.dk covers the launch of Antag Therapeutics in the following article in Danish.